A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

NCT00911859 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Siltuximab11 mg/kg
DRUG: Siltuximab 8.3 mg/kg or 11 mg/kg
DRUG: Velcade (bortezomib)
DRUG: Velcade (bortezomib)
DRUG: Melphalan
DRUG: Melphalan
DRUG: Prednisone
DRUG: Prednisone
DRUG: Velcade (bortezomib)
DRUG: Melphalan
DRUG: Prednisone

Sponsor

Janssen Research & Development, LLC